WEKO3
アイテム
{"_buckets": {"deposit": "c0d2ed60-9e76-4b13-9ebe-f8a32d7af0a4"}, "_deposit": {"created_by": 2, "id": "4695", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "4695"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00004695", "sets": ["9"]}, "author_link": ["19038", "19040", "19039", "19044", "19041", "19042", "19043"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "773", "bibliographicPageStart": "765", "bibliographicVolumeNumber": "21", "bibliographic_titles": [{"bibliographic_title": "Pathology \u0026 Oncology Research"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The mammalian target of rapamycin (mTOR) has recently emerged as a promising target for therapeutic anti-cancer interventions in several human tumors. In present study, we investigated the expression of mTOR, and subsequently examined its relationship with clinicopathological factors and the anti-tumor effect of everolimus (also known as RAD001) in oral squamous cell carcinoma (OSCC). The expression of phosphorylated mTOR (p-mTOR) was immunohistochemically evaluated in specimens obtained from 70 OSCC patients who underwent radical surgery. The relationships between the expression of p-mTOR and clinicopathological factors and survival were determined. We also investigated the effect of everolimus on the OSCC cell lines, SAS, HSC-2, HSC-3, HSC-4, OSC-20, SCC25 and Ca9-22 by the MTT assay. We further evaluated whether mTOR contributed to cell functions by blocking its activity with everolimus, and confirmed the direct target by the Matrigel invasion assay, wound healing assay and Western blotting. p-mTOR was overexpressed in 37 tumors (52.8 %), and correlated with the T classification, N classification, and survival rate (P \u003c 0.05). The treatment with everolimus significantly inhibited cell growth, and significantly reduced the expression of p-mTOR, downstream signaling proteins, and hypoxic related proteins as well as invasion and migration potentials (P \u003c 0.05). The results of the present study suggest that everolimus may represent an attractive approach for the future treatment of OSCC.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Pathology \u0026 Oncology Research, 21(3), pp.765-773; 2015", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer Netherlands"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s12253-014-9888-1", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c Aranyi Lajos Foundation 2015"}, {"subitem_rights": "The original publication is available at www.springerlink.com"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "12194956", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "15322807", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Naruse, Tomofumi"}], "nameIdentifiers": [{"nameIdentifier": "19038", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yanamoto, Souichi"}], "nameIdentifiers": [{"nameIdentifier": "19039", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamada, Shin-ichi"}], "nameIdentifiers": [{"nameIdentifier": "19040", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Rokutanda, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "19041", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawakita, Akiko"}], "nameIdentifiers": [{"nameIdentifier": "19042", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawasaki, Goro"}], "nameIdentifiers": [{"nameIdentifier": "19043", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Umeda, Masahiro"}], "nameIdentifiers": [{"nameIdentifier": "19044", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "POR21_765.pdf", "filesize": [{"value": "1.1 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1100000.0, "url": {"label": "POR21_765.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/4695/files/POR21_765.pdf"}, "version_id": "8e11d961-bca1-4cd4-aece-034e00e45405"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Everolimus", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Hypoxia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "mTOR", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Oral cancer", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/35836", "pubdate": {"attribute_name": "公開日", "attribute_value": "2016-08-01"}, "publish_date": "2016-08-01", "publish_status": "0", "recid": "4695", "relation": {}, "relation_version_is_last": true, "title": ["Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma"], "weko_shared_id": -1}
Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma
http://hdl.handle.net/10069/35836
http://hdl.handle.net/10069/358368e1d12a2-b36c-475b-a154-5d039b40d450
名前 / ファイル | ライセンス | アクション |
---|---|---|
POR21_765.pdf (1.1 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-08-01 | |||||
タイトル | ||||||
タイトル | Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Everolimus | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Hypoxia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | mTOR | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Oral cancer | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Naruse, Tomofumi
× Naruse, Tomofumi× Yanamoto, Souichi× Yamada, Shin-ichi× Rokutanda, Satoshi× Kawakita, Akiko× Kawasaki, Goro× Umeda, Masahiro |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The mammalian target of rapamycin (mTOR) has recently emerged as a promising target for therapeutic anti-cancer interventions in several human tumors. In present study, we investigated the expression of mTOR, and subsequently examined its relationship with clinicopathological factors and the anti-tumor effect of everolimus (also known as RAD001) in oral squamous cell carcinoma (OSCC). The expression of phosphorylated mTOR (p-mTOR) was immunohistochemically evaluated in specimens obtained from 70 OSCC patients who underwent radical surgery. The relationships between the expression of p-mTOR and clinicopathological factors and survival were determined. We also investigated the effect of everolimus on the OSCC cell lines, SAS, HSC-2, HSC-3, HSC-4, OSC-20, SCC25 and Ca9-22 by the MTT assay. We further evaluated whether mTOR contributed to cell functions by blocking its activity with everolimus, and confirmed the direct target by the Matrigel invasion assay, wound healing assay and Western blotting. p-mTOR was overexpressed in 37 tumors (52.8 %), and correlated with the T classification, N classification, and survival rate (P < 0.05). The treatment with everolimus significantly inhibited cell growth, and significantly reduced the expression of p-mTOR, downstream signaling proteins, and hypoxic related proteins as well as invasion and migration potentials (P < 0.05). The results of the present study suggest that everolimus may represent an attractive approach for the future treatment of OSCC. | |||||
書誌情報 |
Pathology & Oncology Research 巻 21, 号 3, p. 765-773, 発行日 2015-07 |
|||||
出版者 | ||||||
出版者 | Springer Netherlands | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 12194956 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 15322807 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s12253-014-9888-1 | |||||
権利 | ||||||
権利情報 | c Aranyi Lajos Foundation 2015 | |||||
権利 | ||||||
権利情報 | The original publication is available at www.springerlink.com | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Pathology & Oncology Research, 21(3), pp.765-773; 2015 |